Journal
BREAST JOURNAL
Volume 27, Issue 4, Pages 314-321Publisher
WILEY
DOI: 10.1111/tbj.14205
Keywords
breast implant associated anaplastic large cell lymphoma; fusions; hematopathology; mutations; next generation sequencing; STAT3‐ JAK2 fusion; structural rearrangements
Categories
Funding
- NCI NIH HHS [P30 CA008748] Funding Source: Medline
Ask authors/readers for more resources
Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) is a distinct subtype characterized by genetic absence of fusions and frequent activation of the JAK-STAT3 pathway. Genetic profiling of BIA-ALCL cases revealed activation of the STAT3-JAK2 fusion, providing further insight into potential targeted therapy options for advanced cases.
Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) is a distinct type of ALCL, and a new provisional entity by the 2016 revision of the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues. In contrast to systemic and primary cutaneous ALCLs, BIA-ALCLs have been genetically characterized by the absence of fusions and frequent activation of the JAK-STAT3 pathway through mutations in JAK1 and STAT3. In this study, we report the results of the genetic profiling of 9 BIA-ALCL cases supporting the role of the JAK-STAT pathway activation in this entity, including the identification of an activating STAT3-JAK2 fusion similar to those recently reported in T-cell lymphoproliferative disorders of the gastrointestinal tract. To our knowledge, this is the first fusion reported in BIA-ALCL, providing further insight into the overall genetic landscape of this rare entity as well as uncovering potential options for targeted therapy in cases with advanced disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available